Eric Karas - Jul 1, 2025 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Signature
/s/ Kathleen Scott, Attorney-in-Fact
Stock symbol
SPRY
Transactions as of
Jul 1, 2025
Transactions value $
-$232,361
Form type
4
Date filed
7/3/2025, 04:21 PM
Previous filing
Jun 20, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Karas Eric Chief Commercial Officer C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO /s/ Kathleen Scott, Attorney-in-Fact 2025-07-03 0001951287

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Options Exercise $22.5K +15K +145.42% $1.50 25.3K Jul 1, 2025 Direct F1
transaction SPRY Common Stock Sale -$255K -15K -59.25% $16.99 10.3K Jul 1, 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -15K -2.68% $0.00 545K Jul 1, 2025 Common Stock 15K $1.50 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 2,619 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2025.
F2 The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024.
F3 The weighted average sale price for the transaction reported was $16.9907, and the range of prices were between $16.71 and $17.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F4 Immediately exercisable.